Self-emulsifying drug delivery systems as a tool to improve solubility and bioavailability of resveratrol

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 117-128

  Balata, Gehan F ^a   Essa, Ebtessam A ^a,b   Shamardl, Hanan A ^a,c   Zaidan, Samira H ^a   Abourehab, Mohammed A S ^a,d  

^a UMM AL QURA UNIVERSITY   (Saudi Arabia)

^b TANTA UNIVERSITY   (Egypt)

^c FAYOUM UNIVERSITY   (Egypt)

^d MINIA UNIVERSITY   (Egypt)

Author keywords

Olive oil; Propylene glycol; Resveratrol; Self emulsifying; Tween 80

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLIVE OIL; POLYSORBATE 80; PROPYLENE GLYCOL; RESVERATROL; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; ANTIOXIDANT; EMULSION; EXCIPIENT; STILBENE DERIVATIVE; SURFACTANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CHEMICAL PARAMETERS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DROPLET SIZE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; DRUG RELEASE; DRUG SOLUBILITY; EMULSIFICATION TIME; EMULSION; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; NONHUMAN; PRECIPITATION; RAT; THERMODYNAMICS; THERMOSTABILITY; TRIACYLGLYCEROL BLOOD LEVEL; WISTAR RAT; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; COMPARATIVE STUDY; DIABETES MELLITUS, EXPERIMENTAL; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; SOLUBILITY;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; DIABETES MELLITUS, EXPERIMENTAL; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; EMULSIONS; EXCIPIENTS; HYPOGLYCEMIC AGENTS; MALE; PARTICLE SIZE; RATS; RATS, WISTAR; SOLUBILITY; STILBENES; SURFACE-ACTIVE AGENTS; THERMODYNAMICS;

EID: 84953851157     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S95905     Document Type: Article

References (48)

1. Farnsworth NR, Akerele O, Bingel AS, Soejarto DD, Guo Z. Medicinal plants in therapy. Bull WHO. 1985;63:965–981.
2. Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release. 2012;158:182–193.
3. Ansari KA, Vavia PR, Trotta F, Cavalli R. Cyclodextrin-based nanosponges for delivery of Resveratrol: In vitro characterisation, stability, cytotoxicity and permeation study. AAPS Pharm Sci Tech. 2011;12(1):279–286.
4. Das S, Das DK. Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Pat Cardiovasc Drug Discov. 2007;2:133–138.
5. Hung LM, Su MJ, Chen JK. Resveratrol protects myocardial ischemia–reperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radic Biol Med. 2004;36:774–781.
6. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493–506.
7. Szkudelski T, Szkudelska K. Anti-diabetic effects of resveratrol. Ann NY Acad Sci. 2011;1215:34–39.
8. Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus – systematic review and meta-analysis. Mol Nutr Food Res. 2015;59(1): 147–159.
9. Boocock DJ, Faust GES, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1246–1252.
10. Kristl J, Teskac K, Caddeo C, Abramović Z, Sentjurc M. Improvement of cellular stress response on Resveratrol in liposomes. Eur J Pharm Biopharm. 2009;73(2):253–259.
11. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3): 413–420.
12. López-Nicolás JM, Núñez-Delicado E, Pérez-López AJ, Barrachina AC, Cuadra-Crespo P. Determination of stoichiometric coefficients and apparent formation constants for β-cyclodextrin complexes of trans-resveratrol using reversed-phase liquid chromatography. J Chromatogr A. 2006;1135(2):158–165.
13. Gokce EH, Korkmaz E, Dellera E, Sandri G, Bonferoni MC, Ozer O. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications. Int J Nanomed. 2012;7:1841–1850.
14. Atanacković MT, Gojković-Bukarica LC, Cvejić JM. Improving the low solubility of resveratrol. Presented at: 18th Scientific Symposium of the Austrian Pharmacological Society (APHAR) joint meeting with the Croatian, Serbian and Slovenian Pharmacological Societies; September 20–21, 2012; Graz, Austria.
15. Bhattacharyya A, Bajpai M. Development and evaluation of a self-emulsifying drug delivery system of amphotericin B. Asian J Pharm. 2012;6(2):124–129.
16. Sapra K, Sapra A, Singh SK, Kakkar S. Self emulsifying drug delivery system: A tool in solubility enhancement of poorly soluble drugs. Indo Global J Pharm Sci. 2012;2(3):313–332.
17. Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. Self emulsifying drug delivery systems: formulation and biopharmaceutical evaluation of an investigational lipophilic compound. Pharm Res. 1992;9(1):87–93.
18. Balakrishnan P, Lee B, Oh DH, et al. Enhanced oral bioavailability of dexibuprofen by a novel solid Self-emulsifying drug delivery system (SEDDS). Eur J Pharm Biopharm. 2009;72(3):539–545.
19. Mei X, Etzler FM, Wang Z. Use of texture analysis to study hydrophilic solvent effects on the mechanical properties of hard gelatin capsules. Int J Pharm. 2006;324(2):128–135.
20. Harshal M, Tanvir S, Dheeraj B, Rajendra W. Design and development of solid self-micro-emulsifying drug delivery system (SEDDS) of fenofibrate. Int J Pharm Pharm Sci. 2011;3(4):163–166.
21. Shah NH, Carvajal MT, Patel CI, Infeld MH, Malick AW. Self-emulsifying drug delivery systems (SEDDS) with polyglycolysed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm. 1994;106(1):15–23.
22. Society of Toxicology. Guiding Principles in the Use of Animals in Toxicology. Reston, VA: Society of Toxicology; 2008. Available from: http://www.toxicology.org/AI/FA/guidingprinciples.pdf. Accessed August 6, 2013.
23. Schmatz R, Mazzanti CM, Spanevello R, et al. Ectonucleotidase and acetylcholinesterase activities in synaptosomes from the cerebral cortex of streptozotocin-induced diabetic rats and treated with resveratrol. Brain Res Bull. 2009;80(6):371–376.
24. Lee ES, Shin MO, Yoon S, Moon JO. Resveratrol inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Arch Pharm Res. 2010;33(6): 925–932.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
26. Biswal S, Sahoo J, Murthy PN, Giradkar RP, Avari JG. Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000. AAPS Pharm Sci Tech. 2008;9(2):563–570.
27. Kallakunta VR, Bandari S, Jukanti R, Veerareddy PR. Oral self emulsifying powder of lercanidipine hydrochloride: Formulation and evaluation. Powd Tech. 2012;221:375–382.
28. Patel AR, Vavia PR. Preparation and in vivo evaluation of SMEDDS (self microemulsifying drug delivery system) containing fenofibrate. AAPS J. 2007;9(3): 344–352.
29. Kassem AA, Marzouk MA, Ammar AA, Elosaily GH. Preparation and in vitro evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) containing clotrimazole. Drug Discov Ther. 2010;4(5): 373–379.
30. Reiss H. Entropy-induced dispersion of bulk liquids. J Colloids Interface Sci. 1975;53(1):61–70.
31. Derle DV, Sagar BSH, Pimpale S. Microemulsion as a vehicle for transdermal permeation of nimesulide. Ind J Pharm Sci. 2006;68(5): 622–625.
32. Rao SVR, Shao J. Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs. I. Formulation development. Int J Pharm. 2008;362(1–2):2–9.
33. Bhikshapathi D, Madhukar P, Kumar BD, Kumar GA. Formulation and characterization of pioglitazone HCl self emulsifying drug delivery system. Der Pharmacia Let. 2013;5(2):292–305.
34. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004;58(3):173–182.
35. Khan F, Islam S, Roni MA, Jalil R. Systematic development of self-emulsifying drug delivery systems of atorvastatin with improved bioavailability. Potential Sci Pharm. 2012;80(4):1027–1043.
36. Suresh PK, Sharma S. Formulation and in-vitro characterization of self-nanoemulsifying drug delivery system of cinnarizine. Int J Compr Pharm. 2011;9(8):1–6.
37. Burtis CA, Ashwood ER. Carbohydrates. In: Saunders WB, editor. Tietz Textbook of Clinical Chemistry. Philadelphia, Pa, USA; 1999: 750–808.
38. Kallakunta VR, Eedara BB, Jukanti R, Ajmeera RK, Suresh Bandari S. A Gelucire 44/14 and labrasol based solid self emulsifying drug delivery system: formulation and evaluation. J Pharm Invest. 2013;43: 185–196.
39. Turan B, Tuncay E, Vassort G. Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies. J Bioenerg Biomembr. 2012;44(2):281–296.
40. Soufi FG, Vardyani M, Sheervalilou R, Mohammadi M, Somi MH. Long-term treatment with resveratrol attenuates oxidative stress pro-inflammatory mediators and apoptosis in streptozotocin-nicotinamide-induced diabetic rats. Gen Physiol Biophys. 2012;31(4):431–438.
41. Miura D, Miura Y, Yagasaki K. Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci. 2003;73(11):1393–1400.
42. Penumathsa SV, Thirunavukkarasu M, Zhan L, et al. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J Cell Mol Med. 2008;12:2350–2361.
43. Brasnyo P, Molnar GA, Mohas M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106(3):383–389.
44. Crandall JP, Oram V, Trandafirescu G, et al. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci. 2012;67(12):1307–1312.
45. Palsamy P, Subramanian S. Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic b-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. J Cell Physiol. 2010;224(2):423–432.
46. Rivera L, Moron R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009;77(6):1053–1063.
47. Do GM, Kwon EY, Kim HJ, Jeon SM, Ha TY, Park T. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun. 2008;374(1):55–59.
48. Kim S, Jin Y, Choi Y, Park T. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol. 2011;81: 1343–1351.